Drug Trial Radar · NCT04481321
Clinical and Molecular Study of Endometriosis and Adenomyosis
Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5,300
Planned (sponsor's estimate)
Start
May 2006
Primary completion
Jun 2040
Study completion Dec 2040
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- URC-CIC Paris Descartes Necker Cochin
- First posted
- Jul 22, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 42 years
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether endometriosis and adenomyosis are progressive diseases, in terms of symptoms (pain, abnormal uterine bleeding and infertility), anatomical lesions size, and recurrences. We also aimed to address molecular questions on immune dialogues between ectopic lesions and the eutopic endometrium, auto-immunity in endometriosis and adenomyosis and the role of the microbiota in their respective pathophysiologies.
Conditions
- Endometriosis
- Adenomyosis
Interventions
Biological/VaccineBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain scores (analog visual scale), quantification of uterine bleeding (number of towels or tampon/day/month) and live birth ratesTime frame: 10 years
- Changes in lesions or recurrences to imaging performed during the gynaecological follow-up of the patientTime frame: 10 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Port Royal, hospital cochin
Paris, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.